NASDAQ · QNCX
Healthcare · Biotechnology
$28.10
Down-$1.29 (-4.59%)
Updated Oct 7, 2026, 12:18 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · QNCX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
QNCX closed at $28.10 after 20 trading sessions, down 4.75% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $29.00 | $29.78 | $28.00 | $28.10 | 22.1K |
| Oct 2, 2026 | $30.20 | $31.06 | $29.20 | $29.20 | 68.38K |
| Oct 1, 2026 | $31.99 | $31.99 | $29.20 | $30.68 | 20.92K |
| Sep 30, 2026 | $31.97 | $32.5923 | $30.62 | $31.01 | 10.68K |
| Sep 29, 2026 | $28.70 | $32.00 | $26.45 | $31.17 | 21.8K |
| Sep 28, 2026 | $30.00 | $31.20 | $26.90 | $29.00 | 40.8K |
| Sep 25, 2026 | $30.40 | $31.00 | $29.98 | $31.00 | 10.34K |
| Sep 24, 2026 | $30.81 | $30.81 | $29.60 | $30.00 | 10.86K |
| Sep 23, 2026 | $31.01 | $31.01 | $29.0251 | $30.15 | 7.59K |
| Sep 22, 2026 | $32.79 | $32.99 | $30.50 | $31.35 | 24K |
| Sep 21, 2026 | $29.46 | $31.00 | $28.5366 | $31.00 | 13.68K |
| Sep 18, 2026 | $27.20 | $30.00 | $27.20 | $29.48 | 48.84K |
| Sep 17, 2026 | $27.17 | $27.83 | $26.62 | $27.01 | 11.88K |
| Sep 16, 2026 | $27.39 | $28.50 | $25.775 | $27.17 | 49.3K |
| Sep 15, 2026 | $28.57 | $29.99 | $27.15 | $28.845 | 15.93K |
| Sep 14, 2026 | $29.28 | $29.28 | $26.995 | $28.59 | 33.57K |
| Sep 11, 2026 | $28.88 | $30.44 | $28.88 | $29.55 | 11.34K |
| Sep 10, 2026 | $30.00 | $30.00 | $28.3101 | $28.96 | 3.63K |
| Sep 9, 2026 | $29.47 | $31.03 | $28.76 | $30.315 | 10.33K |
| Sep 8, 2026 | $31.88 | $31.88 | $29.005 | $29.50 | 12.71K |
The latest Smart Investors Daily articles mentioning QNCX.
Company
Market Activity
Research & News
QNCX research
Company profile and research snapshot.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | Rodman & Renshaw | Buy | — |
| Sep 22, 2026 | Citizens | Market Outperform | — |
| Aug 18, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 29, 2026 | Oppenheimer | Outperform | — |
| Jun 24, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 28, 2026
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome September 28, 2026...
Benzinga · Sep 24, 2026
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Buy rating and announces Price Target of $70.
Benzinga · Sep 22, 2026
Citizens analyst Jonathan Wolleben upgrades Quince Therapeutics (NASDAQ:QNCX) from Market Perform to Market Outperform and announces $77 price target.
Yahoo · Sep 17, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET. The event will feature PH-ILD experts Aaron B. Waxman, MD, PhD (Brigham and Women's Hospital) and Paul Yu, MD, PhD (Massach
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QNCX.
